Evidence map›Paper›PMID 28812136›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2017

Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.

Rehan Ali, Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Ronald Mora, Ali Al Asadi, Juan Carlos Caicedo, Michael Abecassis, Nitin Katariya, Haripriya Maddur and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Personalized lung dosimetry evaluated byJapanese journal of radiology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rehan AliDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Ahsun RiazDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Ahmed GabrDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Nadine AbouchalehDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Ronald MoraDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Ali Al AsadiDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Juan Carlos CaicedoDepartment of Surgery, Division of Transplant Surgery, Northwestern University, Chicago, IL, USA.
Michael AbecassisDepartment of Surgery, Division of Transplant Surgery, Northwestern University, Chicago, IL, USA.
Nitin KatariyaDepartment of Surgery, Division of Transplant Surgery, Northwestern University, Chicago, IL, USA.
Haripriya MaddurDepartment of Medicine, Division of Hepatology, Northwestern University, Chicago, IL, USA.
Laura KulikDepartment of Medicine, Division of Hepatology, Northwestern University, Chicago, IL, USA.
Robert J LewandowskiDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA.
Riad SalemDepartment of Radiology, Section of Interventional Radiology, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. r-salem@northwestern.edu.ORCID http://orcid.org/0000-0001-9745-1825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection.

methodsWith IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed.

resultsForty-one patients met study inclusion criteria. Twenty-six (63%) patients had undergone minor (≤3 hepatic segments) resection while 15 (37%) patients underwent major (>3 hepatic segments) resections. Two patients (5%) had biliary-enteric anastomoses created during surgical resection. The median time from HCC resection to the first radioembolization was 17 months (95% CI: 13-37). The median number of Y90 treatment sessions was 1 (range: 1-5). Ten patients received (entire remnant) lobar Y90 treatment while 31 patients received selective (≤2 hepatic segments) treatment. Grades 1/2/3/4 bilirubin toxicity were seen in nine (22%), four (10%), four (10%), and zero (0%) patients following Y90. No differences in bilirubin toxicities were identified when comparing lobar with selective approaches (P = 0.20). No post-Y90 infectious complications were identified. Median TTP and OS were 11.3 (CI: 6.5-15.5) and 22.1 months (CI: 10.3-31.3), respectively.

conclusionsRadioembolization is a safe and effective method for treating recurrent HCC following surgical resection, with prolonged TTP and promising survival outcomes.

Indexed as

Embolization, TherapeuticAgedCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedTreatment OutcomeYttrium RadioisotopesYttrium-90Yttrium RadioisotopesHepatic resectionHepatocellular carcinomaY90 Radioembolization

Identifiers

PMID28812136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.